Raises FY25 revenue view to $756M-$776M from $739M-$759M, consensus $724.88M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals reports Q4 adjusted EPS $1.63 vs. $1.00 last year
- ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ANI Pharmaceuticals Shares Strategic Insights at Conference
- ANI Pharmaceuticals Projects Strong Growth for 2025
- ANI Pharmaceuticals sees FY24 adjusted EPS, revenue ‘at or above’ guidance